EBV negative Richter's syndrome from a coexistent clone after salvage treatment with alemtuzumab in a CLL patient

American Journal of Hematology

Volumn 81, Issue 9, 2006, Pages 706-712

  Janssens, Ann ^a,b   Berth, Mario ^a   De Paepe, Pascale ^a   Verhasselt, Bruno ^a   Van Roy, Nadine ^a   Noens, Lucien ^a   Philippé, Jan ^a   Offner, Fritz ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Alemtuzumab; B cell chronic lymphocytic leukemia; Richter's syndrome

Indexed keywords

ALEMTUZUMAB; CHLORAMBUCIL; CORTICOSTEROID; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; NUCLEOSIDE ANALOG;

ADULT; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; B CELL LYMPHOMA; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; DISEASE COURSE; EPSTEIN BARR VIRUS; FEMALE; HODGKIN DISEASE; HUMAN; IMMUNOPHENOTYPING; IMMUNOSURVEILLANCE; LARGE CELL LYMPHOMA; LYMPHOCYTE; LYMPHOCYTE TRANSFORMATION; MOLECULAR BIOLOGY; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; RICHTER SYNDROME; SALVAGE THERAPY; T CELL DEPLETION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; CLONE CELLS; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; FLOW CYTOMETRY; HERPESVIRUS 4, HUMAN; HUMANS; LEUKEMIA, B-CELL, CHRONIC; LYMPHOMA, LARGE-CELL; MIDDLE AGED; SYNDROME; TIME FACTORS;

EID: 33748120755     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20712     Document Type: Article

References (31)

1. Oscier D, Gardiner A, Mould S, et al. Multivariate analysis of prognostic factors in CLL: Clinical stage, IGVH gene mutational status and loss or mutations of the p53 gene are independent prognostic factors. Blood 2002;100:1177-1184.
2. D'Onofrio G, Zini G, Bain B. Lymphoproliferative disorders. In: D'Onofrio G, Zini G, Bain B, editors. Morphology of the Blood. Oxford: Butterworth Heinemann; 1998. pp 257-315.
3. Robertson L, Pugh W, O'Brien S, et al. Richter syndrome: A report on 39 patients. J Clin Oncol 1993;11:1985-1989.
4. Gilles F, O'Brien S, Keating M. Chronic lymphocytic leukaemia in (Richter's) transformation. Semin Oncol 1998;25:117-125.
5. Patriarca F, Gaidano G, Capello D, Zaja F, Fanin R, Baccarani M. Occurrence of multiple myeloma after fludarabine treatment of a chronic lymphocytic leukaemia: Evidence of a biclonal derivation and clinical response to autologeous stem cell transplantation. Haematologica 2000;85:982-985.
6. Foon K, Thiruvengadam R, Saven A, Bernstein Z, Gale R. Genetic relatedness of lymphoid malignancies. Ann Intern Med 1993;119:63-73.
7. Keating M, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-H) in patients who have failed fludarabine: Results of a large international study. Blood 2002;99:3554-3561.
8. Rezvany M, Lundin J, Edman P, et al. Long-term follow-up of lymphocyte subsets after subcutaneous alemtuzumab treatment as primary therapy for B-cell chronic lymphocytic leukaemia. Blood 2002;100:207a.
9. Kroft S, Dawson B, McKenna R. Large cell lymphoma transformation of chronic lymphocytic leukaemia/small lymphocytic lymphoma. Am J Clin Pathol 2001;115:385-395.
10. Nakamura N, Abe M. Richter syndrome in B-cell chronic lymphocytic leukaemia. Pathol Int 2003;53:195-203.
11. Mauro F, Foa R, Giannarelli D, et al. Clinical characteristics and outcome of young chronic lymphocytic leukaemia patients: A single institution study of 204 cases. Blood 1999;94:448-454.
12. Cheson B, Vena D, Barrett J, Freidlin B. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphocytic leukaemia. J Clin Oncol 1999;17:2454-2460.
13. Tabuteau S, Garidi R, Fernandes J, Capiod J, Legrand S, Desablens B. Fludarabine and risk of occurrence of Richter syndrome among B-CLL. Blood 2000;96:259b.
14. Robak T, Blonski J, Gora-Tybor J, et al. The occurrence of second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine and alkylating agents. Blood 2003;102:440a.
15. Keating M, O'Brien S, Lerner S, et al. Long-term follow-up of patients with chronic lymphocytic leukaemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998;92:1165-1171.
16. Morrison V, Rai K, Peterson B, et al. Transformation to Richter's syndrome or prolymphocytic leukaemia (PLL) and other second haematological malignancies in patients with chronic lymphocytic leukaemia (CLL): An intergroup study (CALGB 9011). Blood 1999;94:539a.
17. Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of fludarabine, CAP and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukaemia patients. Blood 2001;98:2319-2325.
18. De Levai L, Vivario M, De Prijck B, et al. Distinct clonal origin in two cases of Hodgkin's lymphoma variant of Richter's syndrome with EBV infection. Am J Surg Pathol 2004;28:679-686.
19. Cohen Y, Da'as N, Libster D, Amir G, Berrebi A, Polliak A. Large-cell transformation of chronic lymphocytic leukemia and follicular lymphoma during or soon after treatment with fludarabine-rituximab-containing regimens: Natural history or therapy-related complication. Eur J Haematol 2002;86:80-83.
20. Byrd J, Peterson B, Morrison V, et al. Randomized phase II study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukaemia: Results from Cancer and Leukemia Group B 9712. Blood 2003;101:6-14.
21. Ferrajoli A, O'Brien S, Cortes J, et al. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer 2003;98:773-778.
22. Faderl S, Thomas D, O'Brien S, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory mymphoid malignancies. Blood 2003;101:3413-3415.
23. Ghobrial I, Otterman L, White W. An EBV-lymphoproliferative disorder after therapy with alemtuzumab. NEJM 2003;349:2570-2572.
24. O'Brien S, Kantarjian H, Thomas D, et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukaemia. Cancer 2003;98:2657-2663.
25. Karlsson C, Norin S, Lundin J, et al. Alemtuzumab as first-line therapy in B-cell chronic lymphocytic leukaemia: Long term follow-up of clinical effects, infectious complications and risk of Richter transformation. Hematol J 2004;5:S30.
26. Dal Maso L, Franceschi S. Epidemiology of non-Hogdkin lymphomas and other haemolymphopoietic neoplasms in people with AIDS. Lancet Oncol 2003;4:110-119.
27. Besson C, Goubar A, Gabarre J, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001;98:2339-2344.
28. Kirk O, Pedersen C, Cozzi-Lepri A, et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 2001;98:4250-4251.
29. Loren A, Porter D, Stadtmauer E, Tsai D. Post-transplant lymphoproliferative disorders: A review. Bone Marrow Transplant 2003;31:145-155.
30. Snyder MJ, Stenzel TT, Buckley PJ, et al. Posttransplant lymphoproliferative disorders following nonmyeloablative allogeneic stem cell transplantation. Am J Surg Pathol 2004;28:794-800.
31. Pocock C, Matutes E, Wotherspoon A, Cunningham D, Catovsky D. Fludarabine therapy may precipitate large cell transformation in chronic lymphocytic leukaemia but not in follicular lymphoma. Blood 1998;92:429a.